1.
Cell
; 187(6): 1360-1362, 2024 Mar 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38490180
RESUMO
The mpox outbreak in 2022 launched a vaccination campaign employing an existing vaccine with moderate protection, highlighting the lack of scalable Orthopoxvirus vaccines with optimal protection. In this issue of Cell, Zuiani et al. report pre-clinical findings of an mRNA-based mpox vaccine, paving the way for Phase I/II clinical trials.